Covid-19, prise en charge, pistes thérapeutiques et vaccinales

While at the beginning of 2020, the COVID-19 epidemic was spreading at tremendous speed, many scientific teams set to work around the world. The management of severe acute respiratory syndrome coronavirus 2 infections is based on experimental non-specific (symptomatic) or specific (curative) treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Matusik, Élodie, Ayadi, Mériam, Picard, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442000/
https://www.ncbi.nlm.nih.gov/pubmed/32863556
http://dx.doi.org/10.1016/j.actpha.2020.08.007
_version_ 1783573390690353152
author Matusik, Élodie
Ayadi, Mériam
Picard, Nicolas
author_facet Matusik, Élodie
Ayadi, Mériam
Picard, Nicolas
author_sort Matusik, Élodie
collection PubMed
description While at the beginning of 2020, the COVID-19 epidemic was spreading at tremendous speed, many scientific teams set to work around the world. The management of severe acute respiratory syndrome coronavirus 2 infections is based on experimental non-specific (symptomatic) or specific (curative) treatments. The vaccine will be the key to long-term immunization.
format Online
Article
Text
id pubmed-7442000
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-74420002020-08-24 Covid-19, prise en charge, pistes thérapeutiques et vaccinales Matusik, Élodie Ayadi, Mériam Picard, Nicolas Actual Pharm Article While at the beginning of 2020, the COVID-19 epidemic was spreading at tremendous speed, many scientific teams set to work around the world. The management of severe acute respiratory syndrome coronavirus 2 infections is based on experimental non-specific (symptomatic) or specific (curative) treatments. The vaccine will be the key to long-term immunization. Elsevier Masson SAS. 2020-10 2020-08-21 /pmc/articles/PMC7442000/ /pubmed/32863556 http://dx.doi.org/10.1016/j.actpha.2020.08.007 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Matusik, Élodie
Ayadi, Mériam
Picard, Nicolas
Covid-19, prise en charge, pistes thérapeutiques et vaccinales
title Covid-19, prise en charge, pistes thérapeutiques et vaccinales
title_full Covid-19, prise en charge, pistes thérapeutiques et vaccinales
title_fullStr Covid-19, prise en charge, pistes thérapeutiques et vaccinales
title_full_unstemmed Covid-19, prise en charge, pistes thérapeutiques et vaccinales
title_short Covid-19, prise en charge, pistes thérapeutiques et vaccinales
title_sort covid-19, prise en charge, pistes thérapeutiques et vaccinales
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442000/
https://www.ncbi.nlm.nih.gov/pubmed/32863556
http://dx.doi.org/10.1016/j.actpha.2020.08.007
work_keys_str_mv AT matusikelodie covid19priseenchargepistestherapeutiquesetvaccinales
AT ayadimeriam covid19priseenchargepistestherapeutiquesetvaccinales
AT picardnicolas covid19priseenchargepistestherapeutiquesetvaccinales

Ejemplares similares